United States of America

Our lawyers are reviewing hair relaxer cancer lawsuits for women across the United States. These claims involve women who used chemical hair relaxers or hair straighteners for years and were later diagnosed with uterine cancer, including endometrial cancer, ovarian cancer, or serious uterine fibroids that led to a hysterectomy.

The federal hair relaxer litigation included 12,381 pending lawsuits as of October 1, 2026. The cases are moving through expert discovery and bellwether preparation in the Northern District of Illinois. This litigation has been going on for years, but there is still no global hair relaxer settlement or MDL payout program.  That does not mean our lawyers are not bullish on these cases. We are. It is just moving slowly, which is how it goes sometimes in the MDL mass torts. We still expect a favorable global settlement when all is said and done.

The strongest cases generally involve frequent, long-term use followed by uterine or ovarian cancer, a clear product history, and substantial treatment or reproductive injury.

This page provides updates on Camp Lejeune lawsuits. Our lawyers are still working to give the latest update on the litigation, even though we are no longer taking new cases. Why? Because there is little information out there, and we are staying with victims, including those we do not represent, until the end.

We recently reopened the comments below on October 19 to give you a chance to share your thoughts.

Latest Camp Lejeune Lawsuit Updates for 2026

If you are considering a sexual abuse lawsuit, you want to know what compensation may be available and what makes a claim worth pursuing. Our lawyers look at sex abuse settlement amounts and jury awards, analyzing both example compensation claims and discussing how payouts are calculated in sex abuse lawsuits. We also provide the latest news and updates in this ever-expanding litigation.

Our attorneys handle these claims nationwide. If you are a victim of sexual assault or abuse, call us today at 800-553-8082 or contact us confidentially online. Our sex abuse lawyers can help you pursue compensation and hold the responsible parties accountable.

Table of Contents

Our lawyers stopped accepting new Tylenol autism and ADHD cases after Judge Denise Cote excluded the plaintiffs’ causation experts, a ruling that led to the dismissal of the federal lawsuits.

There is now real reason for renewed optimism. In July 2026, the Second Circuit overturned the judgments resulting from Judge Cote’s expert testimony rulings. The defendants then asked the appeals court to reconsider, and, as we discuss below, that request has now been denied.

But our firm has not yet resumed accepting new Tylenol autism or ADHD claims. The appeals court did not decide that Tylenol causes autism or ADHD, and important questions about the expert evidence still have to be addressed on remand. We will continue following the litigation and reassess our position as the next steps become clearer.

This page is about social media addiction lawsuits and who is eligible to bring a claim. Our lawyers also provide the latest news on social media class action lawsuits (including the ongoing trial in California).

The problem that led to social media lawsuits is that millions of people, too many of whom are children, are addicted to social media platforms such as Facebook, Instagram, Snapchat, and others. For these vulnerable users, social media addiction can be very harmful and lead to things like eating disorders, depression, and, in some cases, suicide.

Now, these companies are facing a wave of new social media lawsuits alleging that they knowingly designed the algorithms of their platforms to lure young people into harmful addictions.

Between 2013 and 2024, contaminated Olympus duodenoscopes infected hundreds of patients at hospitals across the United States. At least 35 people died from these medical scopes.

What happened?  These awful infections were caused by dangerous, drug-resistant bacteria that were extremely difficult to treat.

So you had patients who went to the hospital, often getting diagnostic or therapeutic procedures that they did not think would be a big deal, only to come out with infections that damaged organs, required months of intensive care, or, tragically, proved fatal.

Dupixent lawsuits are now moving forward in federal court for patients who allege the drug caused, accelerated, or unmasked cutaneous T-cell lymphoma and related T-cell lymphomas.

On June 4, 2026, the Judicial Panel on Multidistrict Litigation centralized the federal Dupixent cases in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.

Dupixent, also known as dupilumab, is a biologic medication used to treat atopic dermatitis, asthma, COPD, and a host of other inflammatory conditions. For many patients, Dupixent has provided real relief where other treatments failed. But for some patients, the story has been very different and not one they could have expected.

Our lawyers handle Paraquat lawsuits in all 50 states. This page provides the latest news and updates on Paraquat lawsuits in both state and federal courts. We also give our perspective on where this litigation is heading and provide projected settlement payouts for a viable Paraquat lawsuit.

Continue reading

Uber is defending thousands of sexual assault lawsuits brought by passengers who say they were sexually assaulted by Uber drivers. Plaintiffs are asking what Uber knew about the risk of sexual assault, how it screened drivers, what happened when complaints came in, and whether the company could have done more to keep dangerous drivers off the platform. In the $8.5 million verdict, jurors confirmed what we have been saying all along.

Federal cases have been consolidated in In re: Uber Technologies Inc., Passenger Sexual Assault Litigation, MDL No. 3084, in the Northern District of California. In an MDL, each survivor still has her own lawsuit and her own damages.

By October 2026, 4,916 cases were pending in the federal MDL, with additional claims proceeding in California state court. A federal bellwether case scheduled for October was settled before opening statements. We expect another trial to be scheduled soon.

Bard PowerPort lawsuits allege that defects in implanted port catheters can cause fractures, migration, blood clots, infections, embolisms, and other serious complications. Thousands of product liability lawsuits are now pending against Bard and its parent company, Becton Dickinson, in a federal multidistrict litigation in Arizona.  After a long slog, these cases are now moving forward.

The first bellwether trial ended with a partial defense verdict and a deadlocked jury on the central design defect claim. The most recent trial, Divelbliss v. C.R. Bard, led to a $40 million verdict. It involved an alleged fracture of a silicone Groshong catheter. Five bellwether trials are now expected to run through February 2027.  So far, we are 1-1, with the third trial now getting underway. Our lawyers remain bullish on well-documented fracture, migration, and embolization cases.

This page provides the latest Bard PowerPort lawsuit updates, projected settlement amounts, and information about who may qualify to file a claim.

Contact Information